Viatris Inc. Share Price

Equities

VTRS

US92556V1061

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
11.57 USD +0.87% Intraday chart for Viatris Inc. +2.84% +6.83%
Sales 2024 * 15.22B 1,218B Sales 2025 * 14.98B 1,200B Capitalization 13.74B 1,100B
Net income 2024 * 1.88B 151B Net income 2025 * 989M 79.17B EV / Sales 2024 * 1.78 x
Net Debt 2024 * 13.28B 1,063B Net Debt 2025 * 11.4B 913B EV / Sales 2025 * 1.68 x
P/E ratio 2024 *
7.99 x
P/E ratio 2025 *
13.3 x
Employees 38,000
Yield 2024 *
4.34%
Yield 2025 *
4.52%
Free-Float 97.9%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Viatris Inc.

1 day+0.87%
1 week+2.84%
Current month-3.10%
1 month-0.26%
3 months-3.02%
6 months+28.70%
Current year+6.83%
More quotes
1 week
11.21
Extreme 11.21
11.65
1 month
11.05
Extreme 11.05
12.22
Current year
10.79
Extreme 10.79
13.62
1 year
8.74
Extreme 8.74
13.62
3 years
8.42
Extreme 8.42
16.29
5 years
8.42
Extreme 8.42
28.46
10 years
8.42
Extreme 8.42
76.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 28/12/22
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - 15/11/20
Members of the board TitleAgeSince
Chairman 56 15/11/20
Director/Board Member 68 15/11/20
Director/Board Member 66 15/11/20
More insiders
Date Price Change Volume
26/04/24 11.57 +0.87% 5,166,294
25/04/24 11.47 -0.69% 6,540,893
24/04/24 11.55 +1.67% 7,593,923
23/04/24 11.36 +0.98% 4,675,294
22/04/24 11.25 0.00% 5,099,330

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the Company’s ARV franchise. Its portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas, including key brands and generics, including complex products. It operates around 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
11.57 USD
Average target price
12.4 USD
Spread / Average Target
+7.14%
Consensus